Several clinical trials are now underway to evaluate safety and efficacy of combined PD-1 and CTLA-4 blockade in patients with renal cell carcinoma, non-small cell lung cancer, or melanoma (NCT01783938, NCT01472081, NCT01454102, NCT01024231). Here, PDCD1 is linked to melanoma.